NYU Langone Health
This is a single-site, single-arm, prospective, interventional cohort study using intraoperative ultra-rapid droplet digital polymerase chain reaction (UR- ddPCR) to assess residual IDH1-mutant tumor at the end of surgical resection and, if positive, guide additional resection in real-time.
Inclusion Criteria: * Age ≥ 18 years at the time of consent (any sex) * Newly diagnosed diffuse glioma with either (a) radiographic features consistent with IDH-mutant glioma or (b) prior molecular confirmation of an IDH mutation * Scheduled for tumor tissue biopsy or surgical resection at NYU Langone Health Exclusion Criteria: • Active hepatitis C virus (HCV) infection or suspected/confirmed prion disease (e.g., Creutzfeldt-Jakob disease), as documented in the medical record or by the treating physician, due to biosafety and tissue- handling restrictions
The investigational UR-ddPCR assay will be performed on collected tissue specimens during the participant's scheduled surgical visit.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.